Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
5
×
life sciences
5
×
national blog main
san diego blog main
boston blog main
boston top stories
clinical trials
national top stories
san diego top stories
boston
gene therapy
new york blog main
san diego
san francisco blog main
startups
third rock ventures
vc
abide therapeutics
acetylon pharmaceuticals
allergan
ally bridge group
alnylam
ambys medicines
amylin pharmaceuticals
arena pharmaceuticals
artie suckow
astellas pharma
atlas venture
audentes therapeutics
avidity biosciences
ben cravatt
big data analytics
blackrock
bluebird bio
botox
bristol-myers squibb
casdin capital
cell therapy
constellation pharmaceuticals
deals
What
diseases
5
×
medicines
5
×
new
biotech
drug
genetic
ipo
raises
therapeutics
treat
abide
advance
ago
aiming
ambys
analysis
appointed
big
bio
biologics
biotechs
bring
chief
company
considered
considering
control
data
deadly
deal
debuted
deliver
develop
developing
drugs
dtx
dyne
early
employing
executive
Language
unset
Current search:
medicines
×
biotech
×
" life sciences "
×
diseases
×
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
3 years ago
Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later
@xconomy.com
4 years ago
DTx Pharma Raises $10.6M to Advance New Way to Deliver RNA Drugs
@xconomy.com
5 years ago
Former Zavante Executive Tapped as Abide Therapeutics President
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?